Results 101 to 110 of about 10,075 (184)
Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines
npj VaccinesVaccination has proven to be a valuable tool to combat SARS-CoV-2. However, reports of rare adverse reactions such as thrombosis/thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination have caused scientific, public and media concern.
Joshua Gardner +10 more
doaj +1 more source
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT This case report presents a 58‐year‐old male who developed Parsonage–Turner syndrome (PTS) and vocal cord paresis after receiving the Soberana 2 FINLAY‐FR‐2 COVID‐19 vaccine. The patient experienced escalating pain and weakness in both shoulders and upper limbs after each vaccine dose, with subsequent neurological symptoms including headaches,
Amir‐Hassan Bordbari +2 more
wiley +1 more source
ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates [PDF]
The Lancet, 2021 Elizabeth T Rogawski, McQuade +1 more
openaire +2 more sources
Pharmacoepidemiology and Drug Safety, Volume 34, Issue 11, November 2025.ABSTRACT Purpose Despite Spain's > 2 million COVID‐19 paediatric cases before 2024, few required hospitalisations (8900). We aimed to estimate the effectiveness of two‐dose COVID‐19 vaccinations against hospitalisation ‘with’ and ‘for’ COVID‐19 in paediatrics.
Belén Castillo‐Cano +15 more
wiley +1 more source
Influenza and Other Respiratory Viruses, Volume 19, Issue 11, November 2025.ABSTRACT Background The COVID‐19 pandemic was characterized by waves driven by distinct viral variants, including the Omicron variant, which emerged in October 2021. To formulate effective public health strategies and understand disease spread, accurate estimates of the incubation periods of these variants are important.
Andrei R. Akhmetzhanov +3 more
wiley +1 more source
Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccination
, 2021 The ChAdOx1 nCoV-19 adenoviral vector vaccine to prevent contracting Covid-19 caused by infection with SARS-CoV-2 has been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily leading to venous thromboses.
Kleineberg, Nina N. +13 more
core +1 more source
Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis
ESC Heart Failure, Volume 12, Issue 5, Page 3212-3225, October 2025.Abstract COVID‐19 vaccines have been linked to myocarditis, which, in some circumstances, can be fatal. This systematic review aims to investigate potential causal links between COVID‐19 vaccines and death from myocarditis using post‐mortem analysis.
Nicolas Hulscher +3 more
wiley +1 more source
SARS‐CoV‐2 Antibody Levels and Infections in Multiple Vaccinated Employees Over Time
Journal of Medical Virology, Volume 97, Issue 10, October 2025.ABSTRACT This prospective cohort study aimed to monitor the humoral immune response to SARS‐CoV‐2 proteins over 3 years in relation to repeated vaccination or infection. Quantitative immunoassays traceable to international IgG units were used to measure and compare IgG levels against Wuhan type and Omicron spike‐S1 and nucleocapsid proteins over 3 ...
Ingrid Sander +11 more
wiley +1 more source
VITT after ChAdOx1 nCoV-19 Vaccination
New England Journal of Medicine, 2021 Christian, Weber +2 more
openaire +3 more sources
Clinical Case Reports, Volume 13, Issue 9, September 2025.ABSTRACT Vaccine‐induced thrombotic thrombocytopenia (VITT) has been linked to vector‐based vaccines, but only four cases following whole‐virus vaccines (Sinopharm) have been reported, as far as we are aware. This systematic review aimed to compile the clinical and laboratory results of VITT development after Sinopharm vaccination.
Shafi Rehman +5 more
wiley +1 more source